BENITEC BIOPHARMA ($BNTC) posted quarterly earnings results for Q2 2026 on Thursday, February 12th. The company reported earnings of -$0.26 per share, missing estimates of -$0.23 by $0.03. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $BNTC stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
BENITEC BIOPHARMA Insider Trading Activity
BENITEC BIOPHARMA insiders have traded $BNTC stock on the open market 14 times in the past 6 months. Of those trades, 14 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $BNTC stock by insiders over the last 6 months:
- CAPITAL MANAGEMENT, LLC SUVRETTA has made 14 purchases buying 1,671,845 shares for an estimated $22,442,098 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
BENITEC BIOPHARMA Hedge Fund Activity
We have seen 31 institutional investors add shares of BENITEC BIOPHARMA stock to their portfolio, and 25 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FRANKLIN RESOURCES INC removed 392,328 shares (-15.1%) from their portfolio in Q4 2025, for an estimated $5,284,658
- BLACKROCK, INC. added 226,825 shares (+31.6%) to their portfolio in Q3 2025, for an estimated $3,182,354
- VANGUARD GROUP INC added 182,644 shares (+18.4%) to their portfolio in Q4 2025, for an estimated $2,460,214
- SIMPLIFY ASSET MANAGEMENT INC. added 72,438 shares (+92.0%) to their portfolio in Q4 2025, for an estimated $975,739
- STATE STREET CORP added 57,325 shares (+35.6%) to their portfolio in Q3 2025, for an estimated $804,269
- AWM INVESTMENT COMPANY, INC. added 45,000 shares (+32.6%) to their portfolio in Q3 2025, for an estimated $631,350
- AMERIPRISE FINANCIAL INC added 44,489 shares (+40.5%) to their portfolio in Q3 2025, for an estimated $624,180
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
BENITEC BIOPHARMA Analyst Ratings
Wall Street analysts have issued reports on $BNTC in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 11/24/2025
- JMP Securities issued a "Market Outperform" rating on 09/24/2025
- Oppenheimer issued a "Outperform" rating on 09/16/2025
To track analyst ratings and price targets for BENITEC BIOPHARMA, check out Quiver Quantitative's $BNTC forecast page.
BENITEC BIOPHARMA Price Targets
Multiple analysts have issued price targets for $BNTC recently. We have seen 4 analysts offer price targets for $BNTC in the last 6 months, with a median target of $25.5.
Here are some recent targets:
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $32.0 on 11/24/2025
- Silvan Tuerkcan from Citizens set a target price of $22.0 on 11/04/2025
- Silvan Tuerkcan from JMP Securities set a target price of $20.0 on 09/24/2025
- Andreas Argyrides from Oppenheimer set a target price of $29.0 on 09/16/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
